Clinical Trial Update: Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Lucentis (ranibizumab) for submacular vascularized pigment epithelial detachments associated with retinal pigment epithelial detachment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Pigment Epithelial Detachment

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Clement K. Chan | Conditions: Retinal Pigment Epithelial Detachment | Phase 1 | Status: COMPLETED